Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., reported interim data from the phase IV PRISM II study, showing that treatment with Nuedexta (dextromethorphan hydrobromide) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's.